Latest Findings on the Function of Immune Metabolism in Tumor Immunity

YANG Yang, FAN Dian, ZHENG Bo-hao, ZHOU Sheng-tao

Abstract

Metabolic reprogramming, an important hallmark of cancer, helps cancer achieve rapid proliferation. Metabolic changes in tumors regulate multiple metabolic pathways of immune cells, thereby suppressing antitumor immunity. Recent studies have been focused on in-depth investigation into the changes in the metabolism of glucose, amino acids, and lipids. Researchers have also conducted in-depth exploration of the interactive metabolic regulation of tumor cells and immune cells. Targeting various metabolic mechanisms while combining available anti-tumor therapies and enhancing the anti-tumor effects of immunotherapy by satisfying the metabolic demands of immune cells has offered new perspectives for therapies targeting the immune metabolism of tumors and enhancing anti-tumor immune responses. Studies on novel immune checkpoint molecules and cellular immunotherapies are also ongoing. Herein, we reviewed the latest findings on the mechanisms of immune metabolism underlying tumor immunosuppression and their application in immunotherapy. We also suggested some ideas for the future development of the regulation of immune metabolism.

 

Keywords: Immune metabolism, Tumor microenvironment, Immunotherapy

 

Full Text:

PDF


References


LI X， WENES M， ROMERO P， et al. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. Nat Rev Clin Oncol，2019，16(7): 425–441. doi: 10.1038/s41571-019-0203-7.

CASCONE T， MCKENZIE J A， MBOFUNG R M， et al. Increased tumor glycolysis characterizes immune resistance to adoptive T cell therapy. Cell Metab，2018，27(5): 977–987. doi: 10.1016/j.cmet.2018.02. 024.

ANCEY P B， CONTAT C， MEYLAN E. Glucose transporters in cancer--from tumor cells to the tumor microenvironment. FEBS J，2018，285(16): 2926–2943. doi: 10.1111/febs.14577.

CORBET C， FERON O. Tumour acidosis: from the passenger to the driver's seat. Nat Rev Cancer，2017，17(10): 577–593. doi: 10.1038/nrc. 2017.77.

LIU X， HOFT D F， PENG G. Senescent T cells within suppressive tumor microenvironments: emerging target for tumor immunotherapy. J Clin Invest，2020，130(3): 1073–1083. doi: 10.1172/jci133679.

ANGELIN A， GIL-De-GÓMEZ L， DAHIYA S， et al. Foxp3 reprograms T cell metabolism to function in low-glucose, high-lactate environments. Cell Metab，2017，25(6): 1282–1293.e7. doi: 10.1016/j.cmet.2016.12.018.

LIU X， MO W， YE J， et al. Regulatory T cells trigger effector T cell DNA damage and senescence caused by metabolic competition. Nat Commun， 2018，9(1): 249. doi: 10.1038/s41467-017-02689-5.

CHANG C H， QIU J， O'SULLIVAN D， et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell， 2015，162(6): 1229–1241. doi: 10.1016/j.cell.2015.08.016.

LI W， TANIKAWA T， KRYCZEK I， et al. Aerobic glycolysis controls myeloid-derived suppressor cells and tumor immunity via a specific CEBPB isoform in triple-negative breast cancer. Cell Metab，2018，28(1): 87–103.e6. doi: 10.1016/j.cmet.2018.04.022.

HUSAIN Z， HUANG Y， SETH P， et al. Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. J Immunol，2013，191(3): 1486–1495. doi: 10.4049/jimmunol.1202702.

BOHN T， RAPP S， LUTHER N， et al. Tumor immunoevasion via acidosis-dependent induction of regulatory tumor-associated macrophages. Nat Immunol，2018，19(12): 1319–1329. doi: 10.1038/s41590-018-0226-8.

ZHANG W， WANG G， XU Z G， et al. Lactate is a natural suppressor of RLR signaling by targeting MAVS. Cell，2019，178(1): 176–189.e15. doi: 10.1016/j.cell.2019.05.003.

SUN S， LI H， CHEN J， et al. Lactic acid: no longer an inert and end-product of glycolysis. Physiology (Bethesda)，2017，32(6): 453–463. doi: 10.1152/physiol.00016.2017.

PAJAK B， SIWIAK E， SOŁTYKA M， et al. 2-deoxy-d-glucose and its analogs: from diagnostic to therapeutic agents. Int J Mol Sci，2019，21(1): 234. doi: 10.3390/ijms21010234.

CHRISTOFK H R， VANDER HEIDEN M G， HARRIS M H， et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature，2008，452(7184): 230–233. doi: 10.1038/nature06734.

HOU P P， LUO L J， CHEN H Z， et al. Ectosomal PKM2 promotes HCC by inducing macrophage differentiation and remodeling the tumor microenvironment. Mol Cell，2020，78(6): 1192–1206.e10. doi: 10.1016/j. molcel.2020.05.004.

ZHOU Y， HUANG Z， SU J， et al. Benserazide is a novel inhibitor targeting PKM2 for melanoma treatment. Int J Cancer，2020，147(1): 139–151. doi: 10.1002/ijc.32756.

HUANG R， JING X， HUANG X， et al. Bifunctional naphthoquinone aromatic amide-oxime derivatives exert combined immunotherapeutic and antitumor effects through simultaneous targeting of indoleamine-2, 3-dioxygenase and signal transducer and activator of transcription 3. J Med Chem，2020，63(4): 1544–1563. doi: 10.1021/acs.jmedchem.9b01386.

RIVERA-ÁVALOS E， De LOERA D， ARAUJO-HUITRADO J G， et al. Synthesis of amino acid-naphthoquinones and in vitro studies on cervical and breast cell lines. Molecules，2019，24(23): 4285. doi: 10.3390/molecules24234285.

HSU M C， HUNG W C. Pyruvate kinase M2 fuels multiple aspects of cancer cells: from cellular metabolism, transcriptional regulation to extracellular signaling. Mol Cancer，2018，17(1): 35. doi: 10.1186/s12943-018-0791-3.

CURTIS N J， MOONEY L， HOPCROFT L， et al. Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity. Oncotarget，2017，8(41): 69219–69236. doi: 10.18632/oncotarget.18215.

NABE S， YAMADA T， SUZUKI J， et al. Reinforce the antitumor activity of CD8(+) T cells via glutamine restriction. Cancer Sci，2018，109(12): 3737–3750. doi: 10.1111/cas.13827.

JOHNSON M O， WOLF M M， MADDEN M Z， et al. Distinct regulation of Th17 and Th1 cell differentiation by glutaminase-dependent metabolism. Cell，2018，175(7): 1780–1795.e19. doi: 10.1016/j.cell.2018. 10.001.

LIU P S， WANG H， LI X， et al. α-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. Nat Immunol，2017，18(9): 985–994. doi: 10.1038/ni.3796.

ALTMAN B J， STINE Z E， DANG C V. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer，2016，16(10): 619–634. doi: 10.1038/nrc.2016.71.

GREGORY M A， NEMKOV T， PARK H J， et al. Targeting glutamine metabolism and redox state for leukemia therapy. Clin Cancer Res，2019， 25(13): 4079–4090. doi: 10.1158/1078-0432.Ccr-18-3223.

JACQUE N， RONCHETTI A M， LARRUE C， et al. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. Blood，2015，126(11): 1346–1356. doi: 10.1182/blood-2015-01-621870.

LUENGO A， GUI D Y， VANDER HEIDEN M G. Targeting metabolism for cancer therapy. Cell Chem Biol，2017，24(9): 1161–1180. doi: 10.1016/


Refbacks

  • There are currently no refbacks.